News

Study results may change the understanding and treatment of hormone-based treatment of primary ovarian insufficiency based on genetics.

Pharmacy benefit managers (PBMs) are slowly coming around and putting biosimilars on their formularies. IQVIA estimates that the dearth of a Humira (adalimumab) biosimilars last year cost patients and employers cumulatively $6 billion.

An updated draft guidance says that promotional materials that suggest a biosimilar or reference product is superior “are likely to be false or misleading.” The agency has also warned against making comparisons between biosimilars and those with the interchangeable designation.

Merith Basey, executive director of Patients for Affordable Drug, talks about strategies for lowering the cost of new drugs, especially cell and gene therapy, in a second part of a video interview conducted prior to the June 11-13 AHIP 2024 meeting in Las Vegas.

Merith Basey, M.Sc., executive director of Patients for Affordable Drugs, discusses her group's focus on the monopoly pricing of pharmaceutical companies and bills in Congress addressing patent reform and "pay for delay" strategies, in an interview with MHE previewing the presentation she's co-presenting on June 11 at the AHIP 2024 meeting in Las Vegas.

Elafibranor is the first new medicine approved for primary biliary cholangitis in nearly a decade.

In a randomized clinical trial, the effectiveness of a stepped-care model for delivering palliative care to patients with advanced lung cancer was evaluated.

The FDA approved the expanded age indication for the RSV drug to ages 50 to 59 this past Friday, after initially being approved in the U.S. in May 2023 for RSV patients ages 60 and older.

Rytelo is the first and only telomerase inhibitor approved by the FDA and is expected to be available by the end of summer 2024.

Progentos will use the funding to advance its multiple sclerosis (MS) program through human proof of concept clinical studies and expand its small molecule pipeline to other degenerative conditions.

Fears also extend to the future of Social Security, which may run out by 2036, according to the Social Security Office of Retirement and Disability Policy.

In the latest episode of the Meet the Board podcast series, Managing Editor, Peter Wehrwein, catches up with Chief Clinical Officer at Optum Rx and EAB member, David Calabrese, about his new role alongside his team's progress in improving quality, patient safety and health equity in healthcare.

Three-quarters of disenrollments were due to procedural reasons such as incomplete applications, application errors and inaccurate contact information.

Telehealth companies, Costco, other companies — they are all looking to take advantage of the soaring demand for the weight loss drugs.

A simulation model projects there could savings if patients are switched to lower cost drugs or programs after initial weight loss using GLP-1 drugs.

A growing proportion of small- and medium-sized employers are self-insuring. But with self-insurance, comes fiduciary responsibility and possible scrutiny.

In 2022 alone, an estimated 10.6 million new TB cases were reported, mainly in low-income regions, highlighting the urgent need for further efforts in TB prevention and control.

A SCAN Health Plan "deprescribing" program is working to identify unnecessary prescriptions. In 2023, the program resulted in an estimated $2 million in savings from avoided fractures, falls, visits to the emergency room and other adverse drug events.

Drug developers hope to get in on the action in the hot-selling weight loss drug class

This is the first new recommendation from the American Academy of Pediatrics since the AIDS epidemic began in the 1980s.

The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi for mantle cell lymphoma. The agency has delay a decision on Dupixent in COPD and has set goal dates for zolbetuximab in gastric cancer and zanidatamab in bile duct cancer.

COBRA coverage is not currently considered creditable coverage, so some seniors face Part B penalties. That needs to change.

Healthcare providers and community leaders won’t need a green thumb to implement these changes.

More than 25% of low-income families' earnings go toward healthcare costs.

Some large randomized trials have suggested that taking low doses of aspirin on a daily basis would be an easy, inexpensive way of lowering the risk of getting age-related macular degeneration. Not so a well-designed, placebo-controlled study of septuagenarians conducted in Australia.

On the heels of Winrevair's approval, Gossamer Bio and the Chiesi Group struck a deal to develop seralutinib.

Researchers find a mismatch between demographics of the neighborhoods where the FQHCs with vision care are located and those using the vision services.